Dupixent Label Expands to Include Children Ages 1-11 with Eosinophilic Esophagitis
source: pixabay.com

Dupixent Label Expands to Include Children Ages 1-11 with Eosinophilic Esophagitis

In late January 2024, the U.S. Food and Drug Administration approved a label expansion for Dupixent (dupilumab). Dupixent, a monoclonal antibody targeting IL-4 and IL-13, is currently used to treat…

Continue Reading Dupixent Label Expands to Include Children Ages 1-11 with Eosinophilic Esophagitis